These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
137 related articles for article (PubMed ID: 37843254)
1. Comparison of treatment outcomes between intermittent and daily regimens in non-cavitary nodular bronchiectatic-type Jung J; Chong YP; Lee HJ; Shim TS; Jo K-W Antimicrob Agents Chemother; 2023 Nov; 67(11):e0100323. PubMed ID: 37843254 [TBL] [Abstract][Full Text] [Related]
2. Treatment Outcomes of Cavitary Nodular Bronchiectatic-Type Mycobacterium avium Complex Pulmonary Disease. Chae G; Park YE; Chong YP; Lee HJ; Shim TS; Jo KW Antimicrob Agents Chemother; 2022 Sep; 66(9):e0226121. PubMed ID: 35950842 [TBL] [Abstract][Full Text] [Related]
3. Intermittent antibiotic therapy for nodular bronchiectatic Mycobacterium avium complex lung disease. Jeong BH; Jeon K; Park HY; Kim SY; Lee KS; Huh HJ; Ki CS; Lee NY; Shin SJ; Daley CL; Koh WJ Am J Respir Crit Care Med; 2015 Jan; 191(1):96-103. PubMed ID: 25393520 [TBL] [Abstract][Full Text] [Related]
4. Macrolide/Azalide therapy for nodular/bronchiectatic mycobacterium avium complex lung disease. Wallace RJ; Brown-Elliott BA; McNulty S; Philley JV; Killingley J; Wilson RW; York DS; Shepherd S; Griffith DE Chest; 2014 Aug; 146(2):276-282. PubMed ID: 24457542 [TBL] [Abstract][Full Text] [Related]
5. Intermittent Antibiotic Therapy for Recurrent Nodular Bronchiectatic Mycobacterium avium Complex Lung Disease. Jhun BW; Moon SM; Kim SY; Park HY; Jeon K; Kwon OJ; Huh HJ; Ki CS; Lee NY; Chung MJ; Lee KS; Shin SJ; Daley CL; Koh WJ Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29203483 [TBL] [Abstract][Full Text] [Related]
6. Efficacy of Fluoroquinolones as Substitutes for Ethambutol or Rifampin in the Treatment of Mycobacterium avium Complex Pulmonary Disease According to Radiologic Types. Lee JH; Park YE; Chong YP; Shim TS; Jo KW Antimicrob Agents Chemother; 2022 Feb; 66(2):e0152221. PubMed ID: 34930036 [TBL] [Abstract][Full Text] [Related]
7. Response to Switch from Intermittent Therapy to Daily Therapy for Refractory Nodular Bronchiectatic Mycobacterium avium Complex Lung Disease. Koh WJ; Jeong BH; Jeon K; Park HY; Kim SY; Huh HJ; Ki CS; Lee NY; Shin SJ; Daley CL Antimicrob Agents Chemother; 2015 Aug; 59(8):4994-6. PubMed ID: 25987622 [TBL] [Abstract][Full Text] [Related]
8. Comparison of Treatment Outcomes of Cavitary Mycobacterium avium Complex Pulmonary Disease with Streptomycin or Amikacin Use. Kim SM; Chong YP; Lee HJ; Shim TS; Jo KW Microbiol Spectr; 2023 Jun; 11(3):e0474122. PubMed ID: 37022189 [TBL] [Abstract][Full Text] [Related]
9. The natural history of non-cavitary nodular bronchiectatic Mycobacterium avium complex lung disease. Kwon BS; Lee JH; Koh Y; Kim WS; Song JW; Oh YM; Lee SD; Lee SW; Lee JS; Lim CM; Choi CM; Huh JW; Hong SB; Shim TS; Jo KW Respir Med; 2019 Apr; 150():45-50. PubMed ID: 30961950 [TBL] [Abstract][Full Text] [Related]
10. The Association Between Sputum Culture Conversion and Mortality in Cavitary Mycobacterium avium Complex Pulmonary Disease. Lee JK; Kim S; Chong YP; Lee HJ; Shim TS; Jo KW Chest; 2024 Sep; 166(3):442-451. PubMed ID: 38508335 [TBL] [Abstract][Full Text] [Related]
11. Clinical Outcome with Standard Regimen plus Clofazimine or Moxifloxacin in Cavitary Mycobacterium avium Complex Pulmonary Disease. Park YE; Chong YP; Lee HJ; Shim TS; Jo KW Antimicrob Agents Chemother; 2022 Dec; 66(12):e0052822. PubMed ID: 36326247 [TBL] [Abstract][Full Text] [Related]
12. Long-term natural history of non-cavitary nodular bronchiectatic nontuberculous mycobacterial pulmonary disease. Moon SM; Jhun BW; Baek SY; Kim S; Jeon K; Ko RE; Shin SH; Lee H; Kwon OJ; Huh HJ; Ki CS; Lee NY; Chung MJ; Lee KS; Shin SJ; Daley CL; Koh WJ Respir Med; 2019 May; 151():1-7. PubMed ID: 31047103 [TBL] [Abstract][Full Text] [Related]
13. Multicentre, open label, randomised controlled trial comparing intermittent versus daily treatment for non-cavitary nodular/bronchiectatic Nakagawa T; Hashimoto H; Yagi M; Kogure Y; Sekimizu M; Saito AM; Ogawa K; Inoue Y BMJ Open Respir Res; 2019; 6(1):e000434. PubMed ID: 31258920 [TBL] [Abstract][Full Text] [Related]
15. Treatment of Mycobacterium avium Complex Pulmonary Disease: When Should I Treat and What Therapy Should I Start? Nguyen MH; Daley CL Clin Chest Med; 2023 Dec; 44(4):771-783. PubMed ID: 37890915 [TBL] [Abstract][Full Text] [Related]
16. Microbiological Persistence in Patients With Mycobacterium avium Complex Lung Disease: The Predictors and the Impact on Radiographic Progression. Pan SW; Shu CC; Feng JY; Wang JY; Chan YJ; Yu CJ; Su WJ Clin Infect Dis; 2017 Sep; 65(6):927-934. PubMed ID: 28541556 [TBL] [Abstract][Full Text] [Related]
17. Treatment of Mycobacterium avium Complex (MAC). Griffith DE Semin Respir Crit Care Med; 2018 Jun; 39(3):351-361. PubMed ID: 30071550 [No Abstract] [Full Text] [Related]
18. Low-dosage ethambutol, less than 12.5 mg/kg/day, does not worsen the clinical outcomes of pulmonary Mycobacterium avium and Mycobacterium intracellulare disease: a retrospective cohort study. Watanabe F; Kaburaki S; Furuuchi K; Uesugi F; Fujiwara K; Tanaka Y; Yoshiyama T; Shiraishi Y; Kurashima A; Ohta K; Hanada K; Morimoto K Infection; 2022 Aug; 50(4):879-887. PubMed ID: 35106717 [TBL] [Abstract][Full Text] [Related]
19. Factors that affect sputum conversion and treatment outcome in patients with Mycobacterium avium-intracellulare complex pulmonary disease. Ye JJ; Wu TS; Chiang PC; Lee MH J Microbiol Immunol Infect; 2007 Aug; 40(4):342-8. PubMed ID: 17712469 [TBL] [Abstract][Full Text] [Related]
20. Therapeutic effects of various initial combinations of chemotherapy including clarithromycin against Mycobacterium avium complex pulmonary disease. Hasegawa N; Nishimura T; Ohtani S; Takeshita K; Fukunaga K; Tasaka S; Urano T; Ishii K; Miyairi M; Ishizaka A Chest; 2009 Dec; 136(6):1569-1575. PubMed ID: 19542259 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]